Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Collegium Pharmaceutical (COLL) stock in plain English

Free brief · no signupStart here
COLLPublished Nov 17, 2026
Collegium Pharmaceutical Inc
Healthcare · Drug Manufacturers - Specialty & Generic
Markets prescription pain therapies directly to healthcare providers across the United States.
Assets:
Belbuca and Xtampza ERcore commercial prescription pain medications
Stoughton, Massachusettsheadquarters and administrative operations base
Commercial sales forcededicated field sales team calling on prescribers
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

32
OPS ScoreOperating finances
Latest quote
-2.78%$25.21
$783.42M
25.4×
$816.06M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 17, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was COLL. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Collegium Pharmaceutical (COLL) do?

Collegium Pharmaceutical Inc (COLL) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Markets prescription pain therapies directly to healthcare providers across the United States. Sells pain management medications formulated with technology designed to deter abuse and misuse. It is worth $783.42M on the market and sold $816.06M over the last year.

Market cap
$783.42M
P/E ratio
25.4×
Annual sales
$816.06M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Brief updated
Nov 17, 2026

Brands and businesses behind COLL

  • Belbuca: Generates revenue as a buprenorphine buccal film prescribed to manage severe pain requiring daily opioid therapy.
  • Xtampza ER: Generates sales as an abuse-deterrent extended-release oxycodone capsule prescribed for severe chronic pain.
  • Nucynta: Brings in pharmaceutical revenue as tapentadol tablets prescribed for acute and severe chronic pain relief.
  • Symproic: Produces revenue as an oral prescription tablet designed to treat opioid-induced constipation in adult patients.

COLL’s flags, in plain English

Each flag is a number from Collegium Pharmaceutical’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 17, 2026.

Cheap on Cash Flow

Priced at 2.3 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.

Wide Gross Margin

Gross margin of 59.1% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Still Climbing

Sales up 20.3% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Debt Is Driving

Heavy debt, 407% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.

2 more risk notes open with the free trial. Try it free for 7 days.

Questions about COLL

How big is Collegium Pharmaceutical?

Collegium Pharmaceutical’s market cap is $783.42M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $816.06M: what customers paid the company over the last year, before any costs.

What is COLL’s P/E ratio?

COLL’s P/E ratio is 25.4×. Investors pay about 25.4 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with COLL?

Revenue depends heavily on a small portfolio of pain medications facing patent challenges and generic competition. That is one risk on Collegium Pharmaceutical’s card. Its first risk flag is Debt Is Driving, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Collegium Pharmaceutical’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. COLL’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card